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Abstract
Recent work has demonstrated that the formation of platelet neutrophil complexes (PNCs) affects inflammatory tissue
injury. Vasodilator-stimulated phosphoprotein (VASP) is crucially involved into the control of PNC formation and myocardial
reperfusion injury. Given the clinical importance of hepatic IR injury we pursued the role of VASP during hepatic ischemia
followed by reperfusion. We report here that VASP
2/2 animals demonstrate reduced hepatic IR injury compared to wildtype
(WT) controls. This correlated with serum levels of lactate dehydrogenase (LDH), aspartate (AST) and alanine (ALT)
aminotransferase and the presence of PNCs within ischemic hepatic tissue and could be confirmed using repression of VASP
through siRNA. In studies employing bone marrow chimeric mice we identified hematopoietic VASP to be of crucial
importance for the extent of hepatic injury. Phosphorylation of VASP on Ser
153 through Prostaglandin E1 or on Ser
235
through atrial natriuretic peptide resulted in a significant reduction of hepatic IR injury. This was associated with a reduced
presence of PNCs in ischemic hepatic tissue. Taken together, these studies identified VASP and VASP phosphorylation as
crucial target for future hepatoprotective strategies.
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Introduction
Surgical procedures such as liver transplantation, partial hepatic
resection, hepatic tumor surgery or trauma repair may induce
hepatic ischemia-reperfusion (IR) injury which is associated with
clinically significant reduced liver function [1]. A pathophysiolog-
ical consequence of the cessation of blood supply followed by
reperfusion is cellular damage within the ischemic areas. Several
underlying mechanisms are involved in this process such as
microvascular dysfunction and enhanced leukocyte-endothelial
cell adhesion during the early stages of reperfusion [2]. In
addition, triggered by inflammatory mediators (e.g. cytokines)
neutrophils are activated to cross the endothelial barrier and
translocate into hepatic tissue. This results in the release of
enzymes and reactive oxygen species that aggravate the associated
tissue injury within the hepatic tissue [3,4,5].
Recent work has described an important role for platelet-
neutrophil complexes (PNCs) during inflammatory and ischemic
tissue injury. In a study by Zarbock et al. the authors demonstrate
that the degree of lung injury can be significantly attenuated if the
formation of PNCs is blocked [6]. Furthermore, through platelet
depletion or the injection of activated platelets the role of platelet-
neutrophil complexes (PNCs) that are primed for adhesion,
migration, phagocytosis and intracellular killing was further
delineated in the past [7,8,9]. In a recent study we were able to
describe the role of PNCs during myocardial IR injury [10]. In this
study we identified vasodilator-stimulated phosphoprotein (VASP),
a central cytoskeleton protein affecting actin dynamics, to be a
crucial regulator of PNC formation during the reperfusion phase.
Phosphorylation of VASP on serine 157 (Ser
157) through
prostaglandin E1 (PGE1) or on serine 239 (Ser
239) through atrial
natriuretc peptide (ANP) resulted in a significant attenuation of
this PNC formation [11,12]. Previous work has implicated a
hepatoprotective potential of PGE1 in cirrhotic patients and in
experimental in vivo studies. This hepatoprotective potential was
also described for ANP with a reduction of hepatic apoptosis and
tissue injury through an ANP infusion during hepatic reperfusion
[13,14,15,16].
Given the importance of PNCs for the extent of inflammatory
organ injury and the fact that VASP phosphorylation affects the
formation of PNCs, we analyzed the role of VASP and VASP
phosphorylation during hepatic IR injury. In vivo experimental
data depicted a significant reduction of hepatic IR injury in
VASP
2/2 mice associated with a reduced presence of PNCs.
Targeted repression of VASP using siRNA confirmed these results.
Hepatic IR experiments in bone marrow chimeric animals
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29494identified hematopoietic VASP expression to affect the extent of
hepatic IR injury. Furthermore, phosphorylation of VASP affects
the formation of PNCs and as such the extent of hepatic IR injury.
Materials and Methods
Ethic Statement
All animal protocols were in accordance with the German
guidelines for use of living animals and were approved by the
Institutional Animal Care and Use Committee of the Tu ¨bingen
University Hospital and the Regierungspra ¨sidium Tu ¨bingen.
VASP
2/2 mice were generated, validated and characterized as
described previously [17]. The WT controls (C57BL/6 mice) were
bred as littermates of VASP
2/2 mice.
Murine model of hepatic ischemia
VASP
2/2 mice and littermate controls were selected to be
similar in age-, gender- and weight. After anesthesia was induced
animals were placed on a temperature-controlled and heated table
to maintain body temperature at 37uC. Following midline
laparotomy the liver was exposed. Ligation of the hepatic artery
occured in the ligamentum hepatoduodenale, where the portal
triad was completely and reversible occluded. During the ischemic
period the lobus dexter and lobus caudatus remained perfused via
separate influx and efflux, as described previously [18]. Tissue
damage was determined through blood serum levels of lactate
dehydrogenase (LDH) (Randox, Crumlin, United Kingdom),
aspartate (AST) and alanine aminotransferase (ALT) (Teco
Diagnostics, Anaheim, USA).
Pharmacological compounds used
PGE1 (0.42 mg/kg/h, Sigma-Aldrich, Munich, Germany), atrial
natriuretic peptide (ANP) (0.12 mg/kg/h, Sigma-Aldrich, Munich,
Germany) or vehicle (0.9% NaCl) was administered by intrave-
nous infusion beginning 5 min prior to reperfusion and continuing
1 hour during reperfusion.
In vivo small interfering RNA Repression
To achieve in vivo repression of VASP we used 2.6 mg/g body
weight VASP ON-TARGETplusH SMARTpool Mouse siRNA
dissolved in 5% Glucose-solution. As control served non-targeting
siRNA (Thermo Scientific Dharmacon, Dreieich, Germany) with
at least four mismatches to any human, murine or rat gene. The
siRNA target sequences of the VASP pool were, J-046659-17 with
target sequence UGC CAU UGC UGG AGC CAA A, J-046659-
18 with target sequence AGG AAA UCA UCG AAG UCU U, J-
046659-19 with target sequence GGG CUA CUG UGA UGC
UUU A, J-046659-20 with target sequence GAG CUG AGG
AAG CGG GGU U. SiRNA was administered 24 hours before
ischemia or in subset of experiments 5 min before onset of
reperfusion.
Western blots for VASP and VASP phosphorylation
Mice were injected for stimulation with either 0.42 mg PGE1 or
0.12 mg ANP and blood was taken after 15 min. After spinning at
14,0006g for 10 min to remove cell debris, the pellet was
resuspended in RIPA buffer and protein concentration was
measured. For siRNA experiments the knockdown was validated
by taking blood from mice after 24 h incubation. Primary
antibodies were polyclonal anti-VASP (Cell Signaling), polyclonal
anti-pVASP
153 (Cell Signaling) and anti-pVASP
235 (Cell Signal-
ing). Loading conditions were controlled by polyclonal anti-
GAPDH (Santa Cruz Biotechnology).
Immunohistochemistry of neutrophils and platelets in
murine tissue
Immunohistochemical staining was performed with VectastainH
ABC Kit (Linaris, Wertheim, Germany). After inhibiting the non-
specific binding sites with avidin blocking solution (Vector
Laboratories, CA, USA) the sections were incubated with primary
antibody (polyclonal rabbit anti-mouse CD41, Abcam) over night
at 4uC. Tissue sections were then incubated with biotinylated anti
rabbit IgG for 1 hour followed by VectastainH ABC Reagent for
30 minutes, and then developed using DAB substrate. For
neutrophil staining, the procedure was repeated using rat anti-
mouse neutrophil antibody (rat antimouse Ly-6B2 clone 7/4, AbD
Serotec) and histogreen as substrate (Linaris). Counterstaining was
performed using nuclear fast red (Linaris).
Triphenyltetrazolium chloride staining
After 30 min ischemia and 3 h reperfusion parts of the lobus
medianus were excised washed in ice-cold 0.9% saline, placed on
parafilm, frozen at 220uC for 30 min and cut into 1 mm slices.
The slices were incubated with 1% TTC at 37uC for 30 min and
fixed in 10% formalin. As previously described TTC stains all cells
red except those that are depleted in NADPH and therefore allows
to distinguish viable tissue from ischemic tissue [19].
Generation of bone marrow (BM) chimeras
In short, male donor mice (8–10 weeks old, 20–25 g) were
euthanized, marrow harvested by flushing the marrow cavity and
bone marrow cells were then centrifuged at 4006g for 5 min,
resuspended and counted. Recipient mice (8–10 weeks of age, 20–
25 g) were irradiated with a total dose of 10 Gy from a 137Cs
source. Immediately after irradiation, 10
7 BM cells/recipient were
injected in 0.15 ml 0.9% sodium chloride into the tail vein. The
resulting chimeric mice were housed in microisolators for at least 6
weeks before experimentation and fed with water containing
tetracycline (100 mg/l) in the first two weeks following BM
transplantation. Bone marrow cells were transplanted to generate
(1) [WT R WT] (2) [VASP
2/2 R VASP
2/2] mice as controls and
(3) [WT R VASP
2/2] (4) [VASP
2/2 R WT] chimeric mice [20].
Flow Cytometry
For flow cytometry blood was gently collected by puncture of
the hepatic portal vein and immediately anticoagulated. For the
determination of PNCs citrated whole blood samples were
incubated with a monoclonal anti-CD42b-FITC antibody (clone
Xi1.G5, Emfret Analytics) and with a monoclonal anti-CD15-PE
antibody (clone C3D-1 Santa Cruz Biotechnology). For the
determination of GPIIb/IIIa activation, citrated whole blood
samples were incubated with anti-CD42b-FITC Ab (Emfret) and
with the activation-specific monoclonal Jon-A-PE Ab (clone Jon-A,
Emfret). After 30 minutes incubation at 37uC, samples were fixed
using CellFix (BD Biosciences). Flow cytometry was performed on
a FACScan cytometer (BD Biosciences) and PNC formation as
well as GPIIb/IIIa activation were analyzed according to
previously described principles [21,22]. In all experiments, suitable
isotype Abs were used to adjust for nonspecific Ab binding.
Data analysis
All values are expressed as mean 6 SEM. Using Kolmogorov-
Smirnov test we could show that the measured values were
approximately normally distributed. Statistical significance was
determined using one-way ANOVA followed by Bonferroni’s
multiple-comparison test. Student’s t test was used where
appropriate. A value of P,0.05 was considered significant.
VASP in Liver Ischemia-Reperfusion Injury
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Hepatic IR injury and PNC infiltration is attenuated in
VASP
2/2 mice
In a model of murine hepatic IR injury we exposed previously
characterized VASP
2/2 and controls to 30 minutes of partial liver
ischemia followed by 3 hours of reperfusion [17]. Following this
VASP
2/2 mice demonstrated a significant reduction of LDH, AST
and ALT serum levels compared to controls (Figure 1 A, B and C).
TTC staining of liver tissue sections confirmed these results
(Figure 1 ). Following double staining for PNCs we found a
reduced presence of PNCs within tissue of VASP
2/2 animals
compared to controls (Figure 1 E). To determine the presence of
PNCs within the blood of these animals we determined the
number of PNCs in whole blood samples after 30 minutes
ischemia. We found that the number of PNCs was significantly
lower in VASP
2/2 animals compared to WT controls (Figure S1
A). We also found reduced presence of the active state of the
murine GPIIb/IIIa receptor on the platelet surface of VASP
2/2
animals compared to WT controls, thus confirming previously
published data from our group (Figure S1 B).
To gain further insight into the specific role of VASP we
employed gene targeted repression using siRNA and injected
animals 24 hours prior to the start of the experiment with siVASP
or non-targeting siRNA (siSCR). Repression of VASP was
controlled by Western Blot analysis (Figure S2). We then
subjected the siRNA treated animals to the hepatic IR model
and found reduced LDH, AST and ALT serum levels in siVASP
treated animals compared to siSCR controls (Figure 2 A, B and
C). TTC stained liver tissue sections corroborated the reduced
tissue damage in the siVASP group (Figure 2 D). This reduction
of decreased hepatic damage was associated with a reduced
presence of PNCs within the affected hepatic tissue (Figure 2 E).
Using siVASP immediately during the reperfusion phase however
failed to show a clear effect on IR injury (Figure S6 A, B, C, D
and E).
Hematopoietic VASP repression dampens hepatic IR
injury and PNC infilatration
To gain further insight into the underlying mechanism, we
generated chimeric animals to identify whether tissue specific or
hematopoietic expression would be involved in the previously
observed results. For this, we transferred hematopoietic cells of
VASP
2/2 mice into WT animals (VASP
2/2 WT) and WT
hematopoietic cells in VASP
2/2 mice (WT VASP
2/2), with
WT WT and VASP
2/2 VASP
2/2 transplanted mice as controls.
To control successful transfer of bone marrow we used western
blot analysis (Figure S3). The generated bone marrow chimeric
animals were then subjected to 30 minutes ischemia followed by
3 hours reperfusion. Comparison of the serum parameters LDH,
AST and ALT in bone marrow chimeric mice demonstrated





2/2) animals (Figure 3 A, B and C). TTC stained
liver tissue slices of the different animal groups confirmed the
serum measurements (Figure 3 D). Additionally we found a
reduced presence of PNCs within the hepatic tissue of hemato-
poietic VASP
2/2 mice compared to hematopoietic WT animals.
This correlated with decreased hepatic tissue injury (Figure 3 E).
With these findings we were able to confirm the findings of a
previous study demonstrating the role of VASP during myocardial
ischemia-reperfusion [10]. In this study we found that VASP
within platelets is crucially important for the observed protective
role of VASP repression during IR injury.
Phosphorylation of VASP on Ser
153 using PGE1 dampens
hepatic IR injury
PGE1 induces solid human VASP phosphorylation on Ser
157.I n
an initial experiment we evaluated possible hemodynamic changes
following perfusion with PGE1 but did not find a significant
change of hemodynamic parameters, however we found the
expected murine VASP Ser
153 phosphorylation. We also observed
a cross phosphorylation on VASP Ser
235 through PGE1 (Figure S4
and S5). The PGE1 infusion resulted in a significant reduction in
LDH, AST and ALT (Figure 4 A, B and C) in WT mice, which
was not present in VASP
2/2 animals. TTC staining confirmed the
results of the serum enzyme levels demonstrating reduced hepatic
IR injury (Figure 4 D). We then proceeded to identify the presence
of PNCs within hepatic tissue of these animals, and found that WT
Figure 1. VASP
2/2 animals demonstrate reduced hepatic IR
injury. A) LDH-serum levels of VASP
2/2 and WT mice after 30 minutes
ischemia and 3 hours reperfusion in U/L. B) Correlating serum levels of
AST and C) ALT of VASP
2/2 and WT animals. D) Representative TTC
stained liversections of VASP
2/2 and WT animals E) Histological images
of platelet-neutrophil complexes (neutrophil = blue; platelet = black)
in tissue sections of ischemic tissue of VASP
2/2 and WT animals (Data
are shown as Mean 6 SEM, n=6, *P,0.05; ***P,0.001 as indicated,
tissue sections magnification x400 and x1000 with detail sector
magnification, n=3, one representative of 3 individual experiments is
demonstrated).
doi:10.1371/journal.pone.0029494.g001
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comparison to vehicle treated and PGE1 treated VASP
2/2 mice
(Figure 4 E).
Phosphorylation of VASP on Ser
235 using ANP attenuates
hepatic IR injury
Atrial natriuretic peptide induces human VASP Ser
239 phos-
phorylation in a cGMP dependent fashion [23]. To evaluate
whether this phosphorylation site also holds protective potential
we initially tested for the expected phosphorylation of murine
VASP at Ser
235 (Figure S5). To preclude possible hemodynamic
changes following ANP perfusion we determined the blood
pressure values in ANP treated animals but did not find a
significant change of hemodynamic parameters (Figure S4). When
using ANP to induce VASP Ser
235 phosphorylation in the
reperfusion period we also found a significant reduction of serum
LDH, AST and ALT levels in WT mice. This was not observed in
the VASP
2/2 mice (Figure 5 A, B and C). TTC staining of liver
sections corroborated our findings (Figure 5 D) and correlated with
a reduced number of PNCs within the hepatic tissue of WT
animals treated with ANP compared to vehicle treated and
VASP
2/2 mice (Figure 5 E).
Discussion
We have previously demonstrated that the formation of PNCs
can be influenced through the expression and phosphorylation of
VASP during ischemia-reperfusion of the myocardium [10].
However, the role of VASP during hepatic IR injury remained
unclear to date. As an extension of our previous work we
demonstrate here that hepatic IR injury is significantly influenced
through VASP expression and VASP phosphorylation. This
finding was associated with a reduced presence of PNCs within
hepatic tissue of VASP
2/2 mice and associated with reduced
hepatic injury following reperfusion.
Tissue injury during an acute inflammatory process or ischemia
is significantly affected by the formation of PNCs. Previous work
by Zarbock et al. has recognized the role of PNCs during acute
lung injury and an inhibition of PNC formation results in a
marked decrease of pulmonary injury and improves pulmonary
function [6]. Weissmu ¨ller et al. demonstrated that PNCs are
translocated across the intestinal barrier and that the translocated
platelets are functionally sound to release their contents [24,25]. In
a recent study of our group, we were able to demonstrate that
PNCs are translocated into ischemic myocardium following
reperfusion [10]. In this study we found that the formation of
PNCs was significantly dependent on the phosphorylation of
VASP. The phosphorylation of VASP achieved through ANP or
PGE1 resulted in a reduction of GP IIb/IIIa activation on the
surface of platelets and in a reduced formation of PNCs between
platelets and neutrophils. As a result, the number of circulating
PNCs is significantly attenuated and a reduced number of PNCs is
translocated into ischemic tissue to aggravate the reperfusion
injury. Previous work has shown that the extent of hepatic IR
injury is also determined by the activation status of platelets.
Cywes et al. demonstrated that an inactivation of platelets with
formaldehyde significantly reduces the extent of hepatic IR injury.
Furthermore, an activation of platelets resulted in an increased
hepatic IR injury [26]. A crucial determinant of the adherence of
platelets on the endothelial surface is P-selectin. Animals deficient
of P-selectin demonstrate reduced hepatic reperfusion injury
following ischemia [27]. Furthermore, the adhesion of platelets
to the hepatic endothelium through fibrinogen deposition on
endothelial ICAM-1 aggravates hepatic IR injury [28]. Fibrinogen
binding to platelets is mediated by the GP IIb/IIIa receptor, yet
the surface expression of this receptor is significantly affected by
the phosphorylation of VASP [10]. Yadav et al. also demonstrated
that neutrophils are important contributors to hepatic IR injury
and that the recruitment to the hepatic tissue is dependent on P-
selectin [29]. In addition, the inactivation of neutrophils through a
MAC-1 antibody results in a significant reduction of hepatic IR
injury, this further supports the fact that an interaction of
neutrophils with platelets is an important determinant of IR
injury within the liver and our results are in accordance with these
previous studies [30].
In the presented study, we used ANP to selectively induce
phosphorylation of VASP on Ser
235 and PGE1 to induce VASP
phosphorylation on Ser
153 [23,31]. The protective role of a
Figure 2. In-vivo VASP repression by siRNA dampens hepatic IR
injury. A) LDH-serum levels after hepatic IR in in-vivo targeted
repression of VASP with siRNA (siVASP) or non-targeting siRNA (siSCR)
B) Correlating serum levels of AST and C) ALT of siVASP and siSCR
treated WT animals. D) Representative TTC stained liversections of both
groups. E) Histological images of platelet-neutrophil complexes
(neutrophil = blue; platelet = black) in tissue sections of ischemic
tissue of siVASP and siSCR treated animals (Data are shown as Mean 6
SEM, n=6, *P,0.05; **P,0.01 as indicated, tissue sections magnifica-
tion x400 and x1000 with detail sector magnification, n=3, one
representative of 3 individual experiments is demonstrated).
doi:10.1371/journal.pone.0029494.g002
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injury was demonstrated by several investigators previously. Hafez
et al. were able to show that an infusion of PGE1 resulted in reduced
expression of endothelial adhesion molecules such as ICAM within
the liver and that this intervention resulted in a reduction of the
associated hepatic IR injury[14]. This is in line with previous findings
demonstrating a reduction of IR injury and an attenuation of
intrahepatic inflammationthrough PGE1[32,33]. Aprotective role of
an intervention with ANP during hepatic IR injury was initially
described by Bilzer et al. [34]. The positive effect of ANP on
intrahepatic inflammation and tissue injury was also confirmed by
several other investigators [35,36]. Our results are in accordance with
Figure 3. Hematopoietic VASP repression reduces hepatic IR injury. A) LDH-serum levels in chimeric animals (VASP
2/2RWT and
WTRVASP
2/2) and control transplanted animals after 30 minutes of hepatic ischemia followed by 3 hours reperfusion. B) Correlating serum levels of
AST and C) ALT of the chimeric and control animals D) Representative TTC stained liversections of ischemic tissue. E) Representative histological
images of infracted hepatic areas of infiltrated platelet-neutrophil complexes (neutrophil = blue; platelets = black) of chimeric animals
(VASP
2/2RWT and WTRVASP
2/2) and control transplanted (WTRWT and VASP
2/2R VASP
2/2) animals (Data are shown as Mean 6 SEM, n=6,
*P,0.05; **P,0.01; ***P,0.001 as indicated, tissue sections magnification x400 and x1000 with detail sector magnification, n=3, one representative
of 3 individual experiments is demonstrated).
doi:10.1371/journal.pone.0029494.g003
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ANP during hepatic IR injury. PGE1 and ANP phosphorylate VASP
in platelets and as suchinactivate these platelets. The phosphorylation
of VASP reduces platelet activity and the secretion of their contents.
In addition the expression of L-selectin on the surface of endothelial
cells isattenuated througha phosphorylation of VASP,whichreduces
the attachment of inflammatory cells to the endothelial surface. In a
previous study we were able to demonstrate that tissue specific
repression of VASP increases inflammatory tissue injury [20]. Given
the fact that we were able to achieve a reduction of hepatic
reperfusion injury by approximately 50% demonstrates that tissue
specific VASP holds additional protective function, yet this was not
Figure 4. VASP phosphorylation on Ser
153 using PGE1 dampens hepatic IR injury. A) LDH-serum levels in WT and VASP
2/2 animals after 30
minutes of hepatic ischemia followed by 3 hours reperfusion with infusion of saline (vehicle) or PGE1 during reperfusion. B) Correlating serum levels
of AST and C) ALT of vehicle or PGE1 treated WT and VASP
2/2 animals. D) Representative TTC stained liversections of ischemic tissue. E) Histological
images of platelet-neutrophil complexes (neutrophil = blue; platelet = black) in tissue sections of ischemic liver lobes of vehicle or PGE1 treated WT
and VASP
2/2 animals (Data are shown as Mean 6 SEM, n=6, *P,0.05; **P,0.01; ***P,0.001 as indicated, tissue sections magnification x400 and
x1000 with detail sector magnification, n=3, one representative of 3 individual experiments is demonstrated).
doi:10.1371/journal.pone.0029494.g004
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the observed protective effect of PGE1 or ANP during hepatic IR
injury is mediated through the phosphorylation of the target protein
VASP. This is undermined by the fact that PGE1 or ANP were not
effective in VASP
2/2 animals.
In summary, the results of our study are in line with previous
investigations demonstrating the importance of PNCs for the
extent of inflammatory tissue injury and confirm that an
intervention with PGE1 or ANP might be tissue protective during
hepatic IR injury. VASP phosphorylation on Ser
153 or Ser
235 in
Figure 5. VASP phosphorylation on Ser
235 using ANP dampens hepatic IR injury. A) LDH-serum levels in WT and VASP
2/2 animals after 30
minutes of hepatic ischemia followed by 3 hours reperfusion with infusion of saline (vehicle) or ANP during reperfusion. B) Correlating serum levels of
AST and C) ALT of vehicle or ANP treated WT and VASP
2/2 animals. D) Representative TTC stained liversections of ischemic tissue. E) Histological
images of platelet-neutrophil complexes (neutrophil = blue; platelet = black) in tissue sections of ischemic liver lobes of vehicle or ANP treated WT
and VASP
2/2 animals (Data are shown as Mean 6 SEM, n=6, *P,0.05; **P,0.01; ***P,0.001 as indicated, tissue sections magnification x400 and
x1000 with detail sector magnification, n=3, one representative of 3 individual experiments is demonstrated).
doi:10.1371/journal.pone.0029494.g005
VASP in Liver Ischemia-Reperfusion Injury
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e29494mice resulted in reduced formation of PNCs and as a result the
extent of hepatic IR injury. This work therefore furthers the
understanding of the role of VASP during hepatic IR injury and
might result in novel therapeutic strategies in the future.
Supporting Information
Figure S1 VASP–deficient animals demonstrate reduced
PNC formation and attenuated activation of GP IIb/IIIa
receptor during hepatic IR injury. A) VASP
2/2 and WT
mice were subjected to 30 minutes hepatic ischemia. Number of
PNCs was determined using anti-CD42b-FITC Ab and anti-
CD15-PE Ab after ischemia. B) Activation status of the murine
GPIIb/IIIa receptor evaluated with the activation-specific Jon-A-
PE-Ab during flow cytometry. (Data are shown as Mean6SEM,
n=4; **P,0.01; ***P,0.001 as indicated).
(TIF)
Figure S2 VASP protein expression in WT animals
following siRNA injection. Westernblot analysis of hepatic
tissue in WT animals 24 hours post siVASP or siSCR injection
(n=3).
(TIF)
Figure S3 VASP protein expression in chimeric ani-
mals. Western blot analysis of chimeric animals following BM
transplantation demonstrating VASP expression in hepatic tissue
or whole blood of WTRWT (control) transplanted animals,








2/2 transplanted control animals (Pooled sam-
ples of n=4/ group).
(TIF)
Figure S4 Hemodynamic values determined during the
experimental protocol. Animals were cannulated with a
catheter into the carotid artery and blood pressure measurements
determined during anesthesia, ischemia, reperfusion, injection of
atrial natriuretic peptide (ANP) or prostanglandin E1 ( PGE1) (All
Data are Mean 6 SEM, n=6).
(TIF)
Figure S5 VASP phosphorylation following PGE1 or ANP
treatment. Western blots from whole blood samples from WT
mice taken 15 minutes following injection with either prostaglan-
din E1 (PGE1) or atrial natriuretic peptide (ANP) controlled for
phosphorylation at murine VASP Ser
153 through PGE1 and at
murine VASP Ser
235 through ANP (Pooled samples of n=4/
group).
(TIF)
Figure S6 Liver IR injury in siRNA treated WT animal
during reperfusion. A) LDH-serum levels following hepatic IR
in in-vivo targeted repression (onset 5 min previous reperfusion) of
VASP with siRNA (siVASP) or non-targeting siRNA (siSCR) B)
Correlating serum levels of AST and C) ALT of siVASP and
siSCR treated WT animals. D) Representative TTC stained
images liver sections of both groups. E) ) Histological images of
platelet-neutrophil complexes (neutrophil = blue; platelet =
black) in tissue sections of ischemic liver lobes of siVASP and
siSCR treated animals (Data are shown as Mean 6 SEM, n=6,
*P,0.05 as indicated, tissue sections magnification x400 and
x1000 with detail sector magnification, n=3, one representative of
3 individual experiments is demonstrated).
(TIF)
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